Research Synthesis: Caloric Restriction Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reconcile the Jorgensen 2026 classification: if it is a veterinary RCT and provides only animal/preclinical context for human CR claims, it should not be listed as a 'direct' human clinical source in the Evidence Snapshot; either downgrade directness or move it out of the load-bearing clinical RCT list.
2. Reconcile Kitzman 2016 framing: clarify in-text that it is itself a 2 × 2 factorial RCT in obese older HFpEF patients, but that it functions as a review-grade weight-loss comparison source for the present synthesis because it does not isolate CR as a single intervention; update the tension descriptions accordingly.
3. For each numeric statistic cited (e.g., Reljic 2022 p-value cluster, Houston 2025 ΔTEE -47 ± 353, Weaver 2026 P = 0.007, Mutailipu 2026 P < 0.05), verify against the bundle excerpt and either confirm attribution or flag as unverifiable; exact-statistics calibration requires bundle token or DOI/PMID matching.
4. Clarify in Methods that several Innovation in Aging and similar abstracts (Hsu 2025, Houston 2025, Hsieh 2021, Beavers 2021, Weaver 2021, Kim 2025) come from non-PubMed-indexed sources carried with source_type='corpus' — confirm these are real conference abstracts and add the publisher venue where possible.
5. Tighten the Cross-Domain Synthesis surrogate-vs-hard-outcome paragraph by adding a brief acknowledgment that the cited long-duration RCT it proposes does not currently exist in the literature and therefore the hedged framing is correct; this is currently stated but could be made more explicit.
6. Consider adding a one-sentence note in the Abstract explaining that source-level direction is the conservative coded polarity and may differ from claim-level effect direction seen in any single paper.

Major issues

• The Reviewer/system instructions prohibit me from accepting a manuscript whose own stated conclusion is 'this remains a bounded evidence case' while still scoring source_grounding or claim_evidence_alignment at >=5; the manuscript is honest about its limits but several numeric attributions cannot be fully verified from the reference-only bundle (e.g., Reljic 2022 p-value cluster P = 0.001, P = 0.020, P = 0.004, P = 0.044, P < 0.001, P = 0.005, P = 0.002 — only some are traceable to the bundle excerpt).
• Jorgensen 2026 is a veterinary RCT in diabetic cats coded as 'direct' and tier A1 in both the source-level tier assignments and the Evidence Landscape table; it is not human clinical evidence and should not be classified as direct human clinical RCT. Coding it as 'animal/preclinical context' in the Findings Map while listing it as 'direct' elsewhere is internally contradictory.
• The 'Kitzman 2016 is a systematic review' framing in Cross-Domain Synthesis conflicts with the bundle evidence_type='review' but also with internal manuscript text describing Kitzman 2016 as a '2 × 2 factorial RCT' (the bundle excerpt confirms a 2 × 2 factorial trial, not a review of others); the manuscript inconsistently calls it a review in some places and an RCT in others.

Minor issues

• Abstract opening sentence is unusually long and repeats the '23/37 retained sources are indirect' figure that also appears in the Background and Evidence Snapshot; could be tightened.
• Several claim-trace entries carry truncated excerpts — adequate for audit but borderline for full traceability; consider preserving full evidence spans in a supplement rather than the inline truncated form.
• The Beavers 2022 finding row in the Findings Map lists a P-value of 0.63 with direction=positive; bundle notes 'no treatment differences in gait speed change standard deviations', so combining a P > 0.05 statistic with 'direction=positive' is internally inconsistent.
• Ioannidis 2005 is cited inside the Cross-Domain Synthesis as a methodological reference (surrogate-vs-hard-outcome), but no bundle entry is supplied for it; reference is reasonable scholarly usage but unverifiable from the bundle.
• Bundow 2025 / Hsu 2025 / Houston 2025 / Hsieh 2021 / Kim 2025 / Beavers 2021 / Weaver 2021 entries have source_type='corpus' and lack PMIDs in the bundle; this is acceptable per reference-only convention but worth flagging in Methods that some sources are non-PubMed IDs.
• Kitzman 2016 is flagged as 'directness=review' in the bundle metadata but the paper itself is an RCT; the synthesis should reconcile this by treating it as a primary RCT whose findings are review-level for the current CR question (i.e., not a systematic review of prior RCTs).
• Aneis 2023 is coded 'direction=unclear' in the bundle but appears in a 'positive on body weight' tension framing elsewhere via interpretation; the manuscript should consistently note that the disagreement map uses coded polarity rather than full claim-level effect direction.

Reviewer note

This is a long-form, gatekeeper-tier scoping synthesis with explicit methods, a 37-source evidence corpus, source-level Findings Map, claim traces, cross-domain tension table, and tier/directness coding. The methods and search scope are well described (PRISMA-ScR, deterministic protocol, frozen before rendering, 12-source literature retrieval). The Evidence Landscape/Findings Map functions as a Quantitative Evidence Index with study, endpoint, direction, tier, and source-traced p-values. Strengths: - Research question is specific and bounded: it asks whether cardiometabolic and contextual adjacent evidence support a decision-grade conclusion for CR in adults, and which population/design/directness boundaries keep extrapolation hypothesis-generating. This is directly answered. - Bounded conclusion is honest about the corpus profile (37 sources, 14 direct, 23 adjacent/review/context), explicit that null/positive/negative are not dominant in any outcome class, and that mixed signals cluster in specific slices. Limitations are substantive (mortality RCT absence, single-source outcome classes, surrogate-vs-hard-endpoint gap, missing mechanistic-to-clinical translation). Gaps are specific and actionable (P1–P5 Evidence-Gap Priority list, Next-Study Design Recommendation with sample size and follow-up floors). - Cross-domain tensions are surfaced explicitly: cardiometabolic-vs-frailty/muscle-function divergence, surrogate-vs-hard-outcome, null-vs-positive body composition disagreements, cognitive-and-contextual heterogeneity, safety-vs-benefit divergence by starting adiposity. This is the kind of cross-outcome integration a synthesis at this depth should perform. - Hedging is appropriate throughout (no clinical recommendations beyond the retained corpus). Weaknesses (mostly fixable with bounded edits): - Source classification inconsistency: Jorgensen 2026 is a veterinary diabetic-cat RCT and is sometimes coded 'direct' alongside human RCTs in the Evidence Snapshot but 'animal/preclinical context' in the Findings Map; this should be reconciled to a single consistent treatment. - Kitzman 2016 is coded as a 'review' in the bundle metadata and as a systematic-review source in several manuscript passages, while the bundle excerpt confirms it is itself a primary 2 × 2 factorial RCT; the manuscript should explain that it functions as a review-grade comparative context for the present CR question rather than being literally a systematic review. - Some numeric attributions are stronger than the bundle excerpt allows (Reljic 2022's six-p-value cluster only partially visible in the bundle excerpt; Weaver 2026 explicit P = 0.007 vs the excerpt showing bone-strength findings but not the exact value). - Several Innovation in Aging and Frontiers abstracts are listed with source_type='corpus' rather than PubMed; these are real conference abstracts but the synthetic provenance should be flagged in Methods. Calibration: - Per the source bundle containing full abstracts, the exact statistics calibration rule applies normally (not the reference-only rule); some inline numerics cannot be fully verified from the bundle excerpt and require either revision or bundle token matching. These are bounded fixes. - The clinical-recommendation ceiling is correct (no causal, clinical, or policy claims outrunning the corpus); overclaim verdict = none. - Claim support verdict = partially supported (several numeric attributions need verification but are individually fixable). - Synthesis quality = strong; the manuscript integrates evidence across domains and presents disagreements rather than smoothing them. Verdict: revise. The manuscript is structurally sound, the depth and traceability meet the gatekeeper bar, and the bounded conclusion is appropriate. The revisions required are bounded: (1) reconcile Jorgensen 2026 and Kitzman 2016 classifications, (2) tighten source-traced numerics against the bundle, and (3) clarify corpus sources in Methods. These can be add

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v12-grounded-integrity